Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases.
Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases.
复制标题
DOI：
10.1136/bjophthalmol-2020-317907
复制
发表时间：
2022-08
影响因子：
4.1
通讯作者：
Dua, Harminder Singh
中科院分区：
文献类型：
--
作者：
Deshmukh, Rashmi;Ting, Darren Shu Jeng;Elsahn, Ahmad;Mohammed, Imran;Said, Dalia G.;Dua, Harminder Singh
报告使用外用环孢素Ikervis治疗眼表炎症性疾病（OSIDs）的实际经验。这是一项回顾性研究，研究对象是2016年至2019年期间在诺丁汉女王医疗中心接受Ikervis治疗的sids患者。收集并分析完成至少6个月随访的患者的相关数据，包括人口统计学、适应症、临床参数、结局和不良事件。为了分析目的，临床结果被分类为“成功”（疾病解决或稳定）、“活动性疾病”和“药物不耐受”。纳入463例患者；平均年龄51.1±21.6岁，女性占59.0%。平均随访14.6±9.2个月。最常见的诊断是干眼病（DED， 322例，69.5%），其次是过敏性眼病（AED， 53例，11.4%）和眼粘膜类天疱疮/史蒂文-约翰逊综合征（OMMP/SJS， 38例，8.2%）。343例（74.1%）患者治疗成功，44例（9.5%）患者需要额外治疗，76例（16.4%）患者报告药物不耐受。Ikervis在DED中的疗效最高（264,82.0%），其次是OMMP/SJS（25, 65.8%）和角膜移植术后（7,50.0%,p<0.001）。Logistic回归分析显示，年龄<70岁（p=0.007）、AED （p=0.002）和OMMP/SJS （p=0.001）是Ikervis不耐受的重要预测因素。与DED相比，AED和角膜移植后分别为8.16倍（95% CI, 2.78 ~ 23.99）和13.98倍（95% CI, 4.22 ~ 46.28），更有可能需要额外治疗。Ikervis是一种有效的不使用类固醇的局部治疗方法，用于治疗现实世界中的osid。为了使更多的患者受益，需要耐受性改善的制剂。
To report the real-world experience of using topical ciclosporin, Ikervis, in the management of ocular surface inflammatory diseases (OSIDs). This was a retrospective study of patients treated with Ikervis for OSIDs at the Queen’s Medical Centre, Nottingham, between 2016 and 2019. Relevant data, including demographics, indications, clinical parameters, outcomes and adverse events, were collected and analysed for patients who had completed at least 6 months follow-up. For analytic purpose, clinical outcome was categorised as ‘successful’ (resolved or stable disease), ‘active disease’ and ‘drug intolerance’. 463 patients were included; mean age was 51.1±21.6 years, with a 59.0% female predominance. Mean follow-up was 14.6±9.2 months. The most common diagnosis was dry eye disease (DED; 322, 69.5%), followed by allergic eye disease (AED; 53, 11.4%) and ocular mucous membrane pemphigoid/Steven-Johnson syndrome (OMMP/SJS; 38, 8.2%). Successful treatment was achieved in 343 (74.1%) patients, with 44 (9.5%) requiring additional treatment and 76 (16.4%) reporting drug intolerance. The efficacy of Ikervis was highest in DED (264, 82.0%), followed by OMMP/SJS (25, 65.8%) and post-keratoplasty (7, 50.0%; p<0.001). Logistic regression analysis demonstrated age <70 years (p=0.007), AED (p=0.002) and OMMP/SJS (p=0.001) as significant predictive factors for Ikervis intolerance. AED and post-keratoplasty were 8.16 times (95% CI, 2.78 to 23.99) and 13.98 times (95% CI, 4.22 to 46.28), respectively, more likely to require additional treatment compared with DED. Ikervis is a useful steroid-sparing topical treatment for managing OSIDs in the real-world setting. Preparations with improved tolerability are needed to benefit a larger number of patients.
登录
查看更多内容
DOI：
10.1016/s0195-5616(90)50052-2
发表时间：
1990-05-01
影响因子：
1.9
作者：
KASWAN, RL;SALISBURY, MA
通讯作者：
SALISBURY, MA
影响因子：
2.4
作者：
Inoue, K;Amano, S;Araie, M
通讯作者：
Araie, M
影响因子：
2.8
作者：
HOLLAND, EJ;OLSEN, TW;SUGAR, J
通讯作者：
SUGAR, J
DOI：
10.1080/20016689.2017.1336043
发表时间：
2017-01-01
期刊：
Journal of market access & health policy
影响因子：
--
作者：
Eroglu, Yasmina Iffet
通讯作者：
Eroglu, Yasmina Iffet
影响因子：
2.8
作者：
Behrens, Ashley;Doyle, John J.;Yiu, Samuel C.
通讯作者：
Yiu, Samuel C.